Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $59.46 USD
Change Today +0.49 / 0.83%
Volume 9.7M
As of 6:40 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by MERCK & CO. INC. (MRK) in the last 6 months

Announced 04/9/15
Merck & Co. Inc., Manufacturing Facility In Arecibo
Merger/Acquisition

American Industrial Acquisition Corporation signed an agreement to acquire the manufacturing facility in Arecibo from Merck & Co. Inc. (NYSE:MRK) on April 9, 2015. American Industrial Acquisition Corporation will retain the approximately 200 Merck employees at the Arecibo manufacturing facility.


MRK's price was unchanged after the transaction was announced on 04/9/15.
Investor / Buyer
American Industrial Acquisition Corporation
Creditor / Lender
Merck & Co. Inc.
 
Announced 04/7/15
Arvinas, Inc.
Private Placement

Arvinas, Inc. announced that it will receive funding from new investor Merck & Co., Inc. on April 7, 2015. The terms of the transaction were not disclosed.


MRK's price was unchanged after the transaction was announced on 04/7/15.
Investor / Buyer
Merck & Co. Inc.
 
Announced 03/24/15
10.00B for Merck & Co. Inc.
Buyback

Merck & Co. Inc. (NYSE:MRK) announces a share repurchase program. Under the program, the company will repurchase up to $10,000 million worth of common stock. The repurchases will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The shares will be repurchased for its treasury. The program reinforces company's commitment to deliver increased value to the shareholders and the Board's confidence ...
Read More


MRK's price was unchanged after the transaction was announced on 03/24/15.
 
Announced 02/23/15
106.00M for NGM Biopharmaceuticals, Inc.
Private Placement

NGM Biopharmaceuticals, Inc. announced that it will receive $106 million from new investor Merck & Co. Inc. on February 23, 2015. The investor will acquire 15% stake in the company. The round will be raised at a post-money valuation of $706 million. The funding raised will represent 20% premium to NGM’s most recent financing. The company has issued convertible series E preferred stock Pursuant to Regulation D.


MRK's price was unchanged after the transaction was announced on 02/23/15.
Investor / Buyer
Merck & Co. Inc.
 
Announced 12/18/14
375.00M for Oncoethix SA
Merger/Acquisition

Merck & Co. Inc. (NYSE:MRK) acquired OncoEthix SA from Index Ventures, Edmond de Rothschild Investment Partners, S.A.S., Endeavour II of Endeavour Vision SA, SV Life Sciences Advisers, LLC, and others for approximately $380 million on December 18, 2014. Under the terms of transaction, Merck shall make an upfront payment of up to $110 million to OncoEthix. Additional milestone payments of up to $265 million are contingent upon certain clinical and regulatory events being ...
Read More


MRK's price was unchanged after the transaction was announced on 12/18/14.
Investor / Buyer
Merck & Co. Inc.
Creditor / Lender
BioDiscovery 4 FCPR
Edmond de Rothschild Investment Partners, S.A.S.
Endeavour II
Endeavour Vision SA
Index Ventures
SV Life Sciences Advisers, LLC
 
Announced 12/8/14
9.09B for Cubist Pharmaceuticals Inc.
Merger/Acquisition

Merck & Co. Inc. entered into a definitive agreement to acquire Cubist Pharmaceuticals Inc. (NasdaqGS:CBST) from Bellevue Asset Management AG, Deutsche Asset & Wealth Management Investment GmbH, Federated Equity Management Company of Pennsylvania, HBM Partners Ltd.,Tekla Healthcare Investors and Tekla Life Sciences Investors, funds of Tekla Capital Management LLC, and others for $7.8 billion in cash on December 8, 2014. Merck will acquire the shares of Cubist for $102 ...
Read More


MRK's price was unchanged after the transaction was announced on 12/8/14.
Investor / Buyer
Merck & Co. Inc.
Creditor / Lender
Bellevue Asset Management AG
Deutsche Asset & Wealth Management Investment GmbH
Federated Equity Management Company of Pennsylvania
HBM Partners Ltd.
Tekla Capital Management LLC
Tekla Healthcare Investors
Tekla Life Sciences Investors
Financial Advisor
Goldman, Sachs & Co.
Morgan Stanley & Co. LLC
Legal Advisor
Cravath, Swaine & Moore LLP
Ropes & Gray LLP
 
Announced 12/5/14
Merck & Co. Inc., Merck Manufacturing Facility in Barceloneta, Puerto Rico
Merger/Acquisition

Merial Limited agreed to acquire the Merck manufacturing facility in Barceloneta, Puerto Rico from Merck & Co. Inc. (NYSE:MRK) on December 4, 2014. The proposed transaction requires approval from the United States Federal Trade Commission. If approved, the acquisition will allow Merial to expand its global manufacturing operations and make use of the site's expertise in chewables manufacturing technology. As part of the agreement, Merial will retain the approximately ...
Read More


MRK's price was unchanged after the transaction was announced on 12/5/14.
Investor / Buyer
Merial Limited
Creditor / Lender
Merck & Co. Inc.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $59.46 USD +0.49

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $161.02 USD +1.43
Gilead Sciences Inc $112.46 USD +2.69
GlaxoSmithKline PLC 1,445 GBp +15.00
L'Oreal SA €177.65 EUR +4.05
Pfizer Inc $34.30 USD +0.19
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 15.4x
Price/Sales 4.1x
Price/Book 3.5x
Price/Cash Flow 15.0x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.